Journal of Clinical Medicine · Nov 14, 2026
Serum 25-Hydroxyvitamin D and Risk of All-Cause Mortality in Patients with Chronic Kidney Disease: A Dose–Response Analysis of Prospective Cohorts
By Li Z, Tan W, Xiao Y et al.
Background: Vitamin D metabolic disorders are a critical prognostic factor in patients with chronic kidney disease (CKD). However, the dose–response association between serum 25-hydroxyvitamin D [25(OH)D] concentrations and all-cause mortality in the CKD population remains controversial. This study aimed to quantify this association and explore a preliminary reference serum 25(OH)D range for CKD patients. Methods: We systematically searched PubMed, EMBASE, Web of Science, and Cochrane Library databases up to 10 March 2026, for prospective cohort studies investigating the association between serum 25(OH)D and all-cause mortality in CKD patients. Summary hazard ratios (HRs) were pooled using a random-effects model. Generalized least squares regression models were applied to assess the quantitative dose–response association of serum 25(OH)D with all-cause mortality. Results: A total of 17 prospective cohort studies involving 33,550 CKD patients were included. Higher serum 25(OH)D levels are significantly associated with a lower risk of all-cause mortality (pooled HR = 0.58, 95% CI: 0.53–0.64, p < 0.001; I2 = 52.7%). Dialysis status (p = 0.005) and follow-up duration (p = 0.006) were significant effect modifiers of this association. Dose–response analysis revealed a significant non-linear association with a potential U-shaped pattern (p for non-linearity < 0.001). Conclusions: Serum 25(OH)D suggests a U-shaped association with mortality in CKD; the upward risk at higher concentrations may reflect confounding, with 25(OH)D likely a marker of health status rather than a modifiable risk factor. Findings are constrained by the observational design and moderate between-study heterogeneity; future trials are warranted to validate these results and elucidate relevant mechanisms.